Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Dan Gabriel Duda, Ph.D., D.M.D.

TitleAssociate Professor of Radiation Oncology
InstitutionMassachusetts General Hospital
DepartmentRadiation Oncology
AddressMassachusetts General Hospital
Room CNY 3.407
149 13th Street
Charlestown MA 02129
Phone617/726-4648
Fax617/726-1962

 Biography 
 awards and honors
1997 - 2001Monbusho Graduate Research Fellowship
1998 - Young Investigator Award
2001 - Scholar-in-Training Award
2001 - Travel Grant Award
2002 - 2005Postdoctoral Fellowship
2004 - Travel Grant Award
2005 - 2007Career Development Award for Cancer Research in Angiogenesis
2006 - Scholarship
2008 - 2009Ira J. Spiro Translational Research Award
2009 - Early Career Oncologists / Scientists (ECOS) Grant
2009 - 2011R21-CA139168
2010 - 2011Ira J. Spiro Translational Research Award
2011 - 2012Ira J. Spiro Translational Research Award
2011 - 2014Research Grant RSG-11-073-01-TBG
2011 - 2013Proton Beam Federal Share Individual Grant
2011 - 2016R01-CA159258

 Overview 
 overview
The goal of my research is to gain fundamental insight into solid tumor cellular biology. My area of expertise is the biology of bone marrow-derived cells (BMDCs) in tumor progression. I aim to translate this knowledge into improved therapies by conducting preclinical and clinical studies.
BMDCs may directly or indirectly participate in new vessel formation in tumors, but their involvement in tumor growth has been controversial. I characterized their role in tumors by using genetic tagging with green fluorescent protein combined with state-of-the-art intravital microscopy, and demonstrated that the contribution of BMDCs to functional tumor vessels is marginal, and dependent on tumor type, stage, site, and mouse strain. Moreover, I showed that adult bona fide endothelial precursor cells have limited capacity of forming functional vessels compared to their cord blood counterparts. In addition, I established new methodologies and showed that myeloid cells repair injured vasculature. Finally, in a model of tumor relapse after non-curative radiotherapy, I showed that the major contribution of BMDCs was carried out by monocytes and was mediated by SDF1a/CXCR4 pathway. This work has been supported from 2002 by grants from the Cancer Research Institute, AACR, and NIH (P01, R01 and R21 grants).
In correlative studies performed in multiple clinical trials, I characterized subpopulations of circulating BMDCs. I found that these cells and plasma angiogenic and inflammatory molecules (soluble VEGFR1, soluble collagen IV, SDF1a, PlGF and circulating monocytes) are biomarker candidates for response and resistance to therapy in rectal cancer, recurrent glioblastoma and advanced sarcoma, ovarian and liver cancer. I am currently evaluating these biomarkers in cancer patients in over twenty NCI-sponsored trials, through R21 grants and Proton Beam Federal Share grants.
Against the current wisdom, I have determined that metastasis formation is independent of VEGFR1 activity. Moreover, I used transgenic models to demonstrate that SDF1a/CXCR4 pathway might represent the escape pathway after VEGFR1 inhibition in macrophages by mediating the recruitment of Gr1+ BMDCs. I am currently dissecting the role of SDF1a/CXCR4 pathway in prostate and liver cancer resistance to standard therapies.
I established an in vivo system to investigate the angiogenesis in fat tissue and uncovered the reciprocal regulation between adipogenesis and angiogenesis. Next, I demonstrated the transplantability of fat tissues and the role of VEGF, and measured BMDC-vasculogenesis in adipose tissue using in vivo microscopy and transgenic mice.

I am teaching experimental techniques through daily supervision of nine postdoctoral research fellows, three graduate and nineteen undergraduate students. In the past six years, I have been teaching in the MIT-HMS/HST Program, MGH-Chinese Oncologist Visiting Program, and ASTRO, ESTRO and RTOG translational meetings for residents and clinicians, and in the yearly Methods in Bioengineering course that I am organizing at MGH since 2002.


 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. Benefits of vascular normalization are dose and time dependent--letter. Cancer Res. 2013 Dec 1; 73(23):7144-6.
    View in: PubMed
  2. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1a/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice. Hepatology. 2013 Nov 14.
    View in: PubMed
  3. Chan-On W, Nairism├Ągi ML, Ong CK, Lim WK, Dima S, Pairojkul C, Lim KH, McPherson JR, Cutcutache I, Heng HL, Ooi L, Chung A, Chow P, Cheow PC, Lee SY, Choo SP, Tan IB, Duda D, Nastase A, Myint SS, Wong BH, Gan A, Rajasegaran V, Ng CC, Nagarajan S, Jusakul A, Zhang S, Vohra P, Yu W, Huang D, Sithithaworn P, Yongvanit P, Wongkham S, Khuntikeo N, Bhudhisawasdi V, Popescu I, Rozen SG, Tan P, Teh BT. Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. Nat Genet. 2013 Dec; 45(12):1474-8.
    View in: PubMed
  4. Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K. A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer. Clin Cancer Res. 2013 Dec 1; 19(23):6614-23.
    View in: PubMed
  5. Sahani DV, Jiang T, Hayano K, Duda DG, Catalano OA, Ancukiewicz M, Jain RK, Zhu AX. Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol. 2013; 6(1):51.
    View in: PubMed
  6. Duda DG, Munn LL, Jain RK. Can we identify predictive biomarkers for antiangiogenic therapy of cancer using mathematical modeling? J Natl Cancer Inst. 2013 Jun 5; 105(11):762-5.
    View in: PubMed
  7. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013 Feb 28; 152(5):1065-76.
    View in: PubMed
  8. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013 May 15; 73(10):2943-8.
    View in: PubMed
  9. Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG. Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clin Cancer Res. 2013 Mar 15; 19(6):1557-66.
    View in: PubMed
  10. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17561-6.
    View in: PubMed
  11. Meyerhardt JA, Ancukiewicz M, Abrams TA, Schrag D, Enzinger PC, Chan JA, Kulke MH, Wolpin BM, Goldstein M, Blaszkowsky L, Zhu AX, Elliott M, Regan E, Jain RK, Duda DG. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
    View in: PubMed
  12. Kozin SV, Duda DG, Munn LL, Jain RK. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors? J Natl Cancer Inst. 2012 Jun 20; 104(12):899-905.
    View in: PubMed
  13. Duyverman AM, Steller EJ, Fukumura D, Jain RK, Duda DG. Studying primary tumor-associated fibroblast involvement in cancer metastasis in mice. Nat Protoc. 2012 Apr; 7(4):756-62.
    View in: PubMed
  14. Saylor PJ, Kozak KR, Smith MR, Ancukiewicz MA, Efstathiou JA, Zietman AL, Jain RK, Duda DG. Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer. Oncologist. 2012; 17(2):212-9.
    View in: PubMed
  15. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011 Jul; 91(3):1071-121.
    View in: PubMed
  16. Kozin SV, Duda DG, Munn LL, Jain RK. Is vasculogenesis crucial for the regrowth of irradiated tumours? Nat Rev Cancer. 2011 Jul; 11(7):532.
    View in: PubMed
  17. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol. 2011 May; 8(5):292-301.
    View in: PubMed
  18. Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D, Jain RK. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies? Clin Cancer Res. 2011 Apr 15; 17(8):2074-80.
    View in: PubMed
  19. Hiratsuka S, Goel S, Kamoun WS, Maru Y, Fukumura D, Duda DG, Jain RK. Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation. Proc Natl Acad Sci U S A. 2011 Mar 1; 108(9):3725-30.
    View in: PubMed
  20. Dawson MR, Chae SS, Jain RK, Duda DG. Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res. 2011; 1(2):144-54.
    View in: PubMed
  21. Hiratsuka S, Duda DG, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A. 2011 Jan 4; 108(1):302-7.
    View in: PubMed
  22. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, Jain RK. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A. 2010 Dec 14; 107(50):21677-82.
    View in: PubMed
  23. Yoon SS, Duda DG, Karl DL, Kim TM, Kambadakone AR, Chen YL, Rothrock C, Rosenberg AE, Nielsen GP, Kirsch DG, Choy E, Harmon DC, Hornicek FJ, Dreyfuss J, Ancukiewicz M, Sahani DV, Park PJ, Jain RK, Delaney TF. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):1081-90.
    View in: PubMed
  24. Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011 Feb 15; 17(4):918-27.
    View in: PubMed
  25. Kozin SV, Kamoun WS, Huang Y, Dawson MR, Jain RK, Duda DG. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 2010 Jul 15; 70(14):5679-85.
    View in: PubMed
  26. Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res. 2010 Jul 15; 70(14):5670-3.
    View in: PubMed
  27. Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M, Tyler D, Mantyh C, Shellito P, Clark JW, Jain RK. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010; 15(6):577-83.
    View in: PubMed
  28. Duda DG, Ancukiewicz M, Jain RK. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers? J Clin Oncol. 2010 Jan 10; 28(2):183-5.
    View in: PubMed
  29. Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res. 2009 Oct 15; 69(20):7905-10.
    View in: PubMed
  30. Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK. VEGFR1 activity modulates myeloid cell infiltration in growing lung metastases but is not required for spontaneous metastasis formation. PLoS One. 2009; 4(9):e6525.
    View in: PubMed
  31. Dawson MR, Duda DG, Fukumura D, Jain RK. VEGFR1-activity-independent metastasis formation. Nature. 2009 Sep 17; 461(7262):E4; discussion E5.
    View in: PubMed
  32. Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J. 2009 Jul-Aug; 15(4):263-8.
    View in: PubMed
  33. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009 Jul 1; 69(13):5296-300.
    View in: PubMed
  34. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009 Jun; 6(6):327-38.
    View in: PubMed
  35. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3020-6.
    View in: PubMed
  36. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35.
    View in: PubMed
  37. Jones R, Capen DE, Jacobson M, Cohen KS, Scadden DT, Duda DG. VEGFR2+PDGFRbeta+ circulating precursor cells participate in capillary restoration after hyperoxia acute lung injury (HALI). J Cell Mol Med. 2009 Sep; 13(9B):3720-9.
    View in: PubMed
  38. Perentes JY, Duda DG, Jain RK. Visualizing anti-tumor immune responses in vivo. Dis Model Mech. 2009 Mar-Apr; 2(3-4):107-10.
    View in: PubMed
  39. Huang P, Duda DG, Jain RK, Fukumura D. Histopathologic findings and establishment of novel tumor lines from spontaneous tumors in FVB/N mice. Comp Med. 2008 Jun; 58(3):253-63.
    View in: PubMed
  40. Jones RC, Capen D, Petersen B, Jain RK, Duda DG. A protocol for a lung neovascularization model in rodents. Nat Protoc. 2008; 3(3):378-87.
    View in: PubMed
  41. Jones RC, Capen DE, Cohen KS, Munn LL, Jain RK, Duda DG. A protocol for phenotypic detection and characterization of vascular cells of different origins in a lung neovascularization model in rodents. Nat Protoc. 2008; 3(3):388-97.
    View in: PubMed
  42. Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, Jain RK. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood. 2008 Feb 1; 111(3):1302-5.
    View in: PubMed
  43. Duda DG, Jain RK, Willett CG. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol. 2007 Sep 10; 25(26):4033-42.
    View in: PubMed
  44. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007 Aug; 8(8):610-22.
    View in: PubMed
  45. Willett CG, Duda DG, Czito BG, Bendell JC, Clark JW, Jain RK. Targeted therapy in rectal cancer. Oncology (Williston Park). 2007 Aug; 21(9):1055-65; discussion 1065, 1070, 1075 passim.
    View in: PubMed
  46. Duda DG. American Association for Cancer Research 98th Annual Meeting. Angiogenesis and anti-angiogenesis in cancer. IDrugs. 2007 Jun; 10(6):366-9.
    View in: PubMed
  47. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med. 2007 Jun; 13(6):223-30.
    View in: PubMed
  48. Duda DG, Cohen KS, Scadden DT, Jain RK. A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood. Nat Protoc. 2007; 2(4):805-10.
    View in: PubMed
  49. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
    View in: PubMed
  50. Hagendoorn J, Padera TP, Yock TI, Nielsen GP, di Tomaso E, Duda DG, Delaney TF, Gaissert HA, Pearce J, Rosenberg AE, Jain RK, Ebb DH. Platelet-derived growth factor receptor-beta in Gorham's disease. Nat Clin Pract Oncol. 2006 Dec; 3(12):693-7.
    View in: PubMed
  51. Willett CG, Kozin SV, Duda DG, di Tomaso E, Kozak KR, Boucher Y, Jain RK. Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol. 2006 Oct; 33(5 Suppl 10):S35-40.
    View in: PubMed
  52. Duda DG. Antiangiogenesis and drug delivery to tumors: bench to bedside and back. Cancer Res. 2006 Apr 15; 66(8):3967-70.
    View in: PubMed
  53. Duda DG, Cohen KS, di Tomaso E, Au P, Klein RJ, Scadden DT, Willett CG, Jain RK. Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol. 2006 Mar 20; 24(9):1449-53.
    View in: PubMed
  54. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG, Hoshida T, Fukuyama S, Hamada H, Matsuno S. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther. 2006 Mar; 13(3):242-52.
    View in: PubMed
  55. Kisucka J, Butterfield CE, Duda DG, Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK, Folkman J, Wagner DD. Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):855-60.
    View in: PubMed
  56. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006 Jan; 3(1):24-40.
    View in: PubMed
  57. Duda DG, Cohen KS, Kozin SV, Perentes JY, Fukumura D, Scadden DT, Jain RK. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood. 2006 Apr 1; 107(7):2774-6.
    View in: PubMed
  58. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005 Nov 1; 23(31):8136-9.
    View in: PubMed
  59. Jain RK, Au P, Tam J, Duda DG, Fukumura D. Engineering vascularized tissue. Nat Biotechnol. 2005 Jul; 23(7):821-3.
    View in: PubMed
  60. Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK. Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med. 2005 Jun; 11(6):678-82.
    View in: PubMed
  61. Duda DG, Jain RK. Pleiotropy of tissue-specific growth factors: from neurons to vessels via the bone marrow. J Clin Invest. 2005 Mar; 115(3):596-8.
    View in: PubMed
  62. Duda DG, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, Seed B, Jain RK. Differential transplantability of tumor-associated stromal cells. Cancer Res. 2004 Sep 1; 64(17):5920-4.
    View in: PubMed
  63. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004 Apr; 10(4):143-5.
    View in: PubMed
  64. Sunamura M, Lefter LP, Duda DG, Morita R, Inoue H, Yokoyama T, Yatsuoka T, Abe T, Egawa S, Furukawa T, Fukushige S, Oshimura M, Horii A, Matsuno S. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma. Pancreas. 2004 Apr; 28(3):311-6.
    View in: PubMed
  65. Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004 Feb; 10(2):145-7.
    View in: PubMed
  66. Duda DG, Sunamura M, Lefter LP, Furukawa T, Yokoyama T, Yatsuoka T, Abe T, Inoue H, Motoi F, Egawa S, Matsuno S, Horii A. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene. 2003 Oct 9; 22(44):6857-64.
    View in: PubMed
  67. Fukumura D, Ushiyama A, Duda DG, Xu L, Tam J, Krishna V, Chatterjee K, Garkavtsev I, Jain RK. Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesis. Circ Res. 2003 Oct 31; 93(9):e88-97.
    View in: PubMed
  68. Jain RK, Duda DG. Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell. 2003 Jun; 3(6):515-6.
    View in: PubMed
  69. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi J, Matsuno S, Shibahara S, Abraham NG. Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer. Angiogenesis. 2003; 6(1):15-24.
    View in: PubMed
  70. Hoshida T, Sunamura M, Duda DG, Egawa S, Miyazaki S, Shineha R, Hamada H, Ohtani H, Satomi S, Matsuno S. Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas. 2002 Aug; 25(2):111-21.
    View in: PubMed
  71. Lefter LP, Furukawa T, Sunamura M, Duda DG, Takeda K, Kotobuki N, Oshimura M, Matsuno S, Horii A. Suppression of the tumorigenic phenotype by chromosome 18 transfer into pancreatic cancer cell lines. Genes Chromosomes Cancer. 2002 Jun; 34(2):234-42.
    View in: PubMed
  72. Duda DG, Sunamura M, Lozonschi L, Yokoyama T, Yatsuoka T, Motoi F, Horii A, Tani K, Asano S, Nakamura Y, Matsuno S. Overexpression of the p53-inducible brain-specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis. Br J Cancer. 2002 Feb 1; 86(3):490-6.
    View in: PubMed
  73. Sunamura M, Yatsuoka T, Motoi F, Duda DG, Kimura M, Abe T, Yokoyama T, Inoue H, Oonuma M, Takeda K, Matsuno S. Gene therapy for pancreatic cancer based on genetic characterization of the disease. J Hepatobiliary Pancreat Surg. 2002; 9(1):32-8.
    View in: PubMed
  74. Ding L, Sunamura M, Kodama T, Yamauchi J, Duda DG, Shimamura H, Shibuya K, Takeda K, Matsuno S. In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells. Br J Cancer. 2001 Aug 3; 85(3):431-8.
    View in: PubMed
  75. Sunamura M, Sun L, Lozonschi L, Duda DG, Kodama T, Matsumoto G, Shimamura H, Takeda K, Kobari M, Hamada H, Matsuno S. The antiangiogenesis effect of interleukin 12 during early growth of human pancreatic cancer in SCID mice. Pancreas. 2000 Apr; 20(3):227-33.
    View in: PubMed
  76. Duda DG, Sunamura M, Lozonschi L, Kodama T, Egawa S, Matsumoto G, Shimamura H, Shibuya K, Takeda K, Matsuno S. Direct in vitro evidence and in vivo analysis of the antiangiogenesis effects of interleukin 12. Cancer Res. 2000 Feb 15; 60(4):1111-6.
    View in: PubMed
  77. Motoi F, Sunamura M, Ding L, Duda DG, Yoshida Y, Zhang W, Matsuno S, Hamada H. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum Gene Ther. 2000 Jan 20; 11(2):223-35.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Duda's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_